Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced or Metastatic Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; PALB2 Gene Mutation Interventions: Drug: Niraparib + Elacestrant; Drug: Niraparib Sponsors: German Breast Group; Stemline Therapeutics, Inc.; GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Germany Health | HER2 | Hormones | Oral Cancer | Research